Starling Oncology STLN
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 27th percentile, 5-year average -23.5x
Near the bottom of its 5-year range · 4th percentile, 5-year average -1.5x
Above its usual level · 65th percentile, 5-year average 1.0x
#1771 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -26.35 | – | -1.51 | 4% (cheaper than usual) | – |
| PE | -22.52 | -53.93 | -23.52 | 27% (cheaper than usual) | – |
| PS | 1.13 | 0.87 | 1.03 | 65% (pricier than usual) | #1771 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on STLN.